We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Generics Behaving Badly: Carve Outs, Off-Label Uses

Law360 (March 24, 2009, 12:00 AM EDT) -- Patents have long been the crown jewels of the pharma industry. They protect pioneer therapies from generic competition and underwrite the enormous investment required for new drug research and development.

However, with an estimated $65 billion of drugs coming off patent protection in the next five years, generics stand ready to cash in on this bonanza. As the competitive landscape undergoes enormous changes, pioneers need to coordinate their IP and regulatory strategies to protect new investments in old drugs.

Hatch-Waxman: Then and Now

For the past...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.